Vimarsana
Biggest News Aggregation in the World

Jeffreys Berger News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Jeffreys Berger. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Jeffreys Berger Today - Breaking & Trending Today

Thrombosis in Hospitalized Patients With COVID-19 in a New York City Health System | Coagulation Disorders | JAMA - Vimarsana News

Thrombosis in Hospitalized Patients With COVID-19 in a New York City Health System | Coagulation Disorders | JAMA

This study examines the incidence of and risk factors for venous and arterial thrombosis in patients hospitalized with COVID-19 in 4 New York City hospitals.

NYU Langone's Leading Cardiac Specialists Present Latest Research at the American Heart Association's Scientific Sessions 2022 - Vimarsana News

NYU Langone's Leading Cardiac Specialists Present Latest Research at the American Heart Association's Scientific Sessions 2022

/PRNewswire/ -- Experts from NYU Langone Health presented their latest clinical findings and research discoveries at the American Heart Association's...

Are Dermatologists Interested in Managing CVD Risk in Psoriasis? - Vimarsana News

Are Dermatologists Interested in Managing CVD Risk in Psoriasis?

The authors of the study see their findings as an early but promising step in finding better models to improve cardiovascular outcomes for patients with psoriatic disease.

Adding a P2Y12 Inhibitor Does Not Improve Outcomes in COVID-19 - Vimarsana News

Adding a P2Y12 Inhibitor Does Not Improve Outcomes in COVID-19

TUESDAY, Jan. 18, 2022 (HealthDay News) -- The addition of a P2Y12 inhibitor to anticoagulant therapy does not improve organ support-free days among non-critically ill patients hospitalized for COVID-19, according

Source: psu.edu
Psoriasis Patients, Docs Want to Do More to Prevent Heart Problems - Vimarsana News

Psoriasis Patients, Docs Want to Do More to Prevent Heart Problems

Despite well-known cardiovascular risks, most patients currently undertreated